Checkmate Pharmaceuticals, Inc.
CMPIDelisted May 31, 2022- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001651431
Checkmate Pharmaceuticals, Inc. was delisted on May 31, 2022; its insiders filed their last Form 4 on May 31, 2022; 26 institutions reported holding it in 13F filings for Q1 2022, worth $54.8M in total; no superinvestor held it.
13F holders, Q1 2022
Institutional positions in Checkmate Pharmaceuticals, Inc. as of Mar 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 26
- +1 vs. Q4 2021
- Shares held
- 17.2M
- +1.04M (+6.5%) vs. Q4 2021
- Total value
- $54.8M
- +$8.48M (+18.3%) vs. Q4 2021
- New holders
- 4
- 3 more added
- Sold out
- 3
- 9 more reduced
Compare with Q4 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CMPI on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 26 | $54.8M |
| Q4 2021 | 25 | $46.3M |
| Q3 2021 | 32 | $64.5M |
| Q2 2021 | 34 | $97.3M |
| Q1 2021 | 37 | $202.5M |
Institutions, Q1 2022
Shares, value and share of portfolio for each institution holding Checkmate Pharmaceuticals, Inc.; share changes are against Q4 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Bank of America Corp | 1 | $0 | 0.00% | −1,111−99.9% | Reduced |
| Wells Fargo & Company | 33 | $0 | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 49 | $0 | 0.00% | +49 | New |
| UBS Group AG | 183 | $1.00K | 0.00% | −922−83.4% | Reduced |
| Johnson Midwest Financial, LLC | 200 | $1.00K | 0.00% | 00.0% | Unchanged |
| US Bancorp | 2,000 | $6.00K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 1,940 | $6.00K | 0.00% | +1,940 | New |
| Morgan Stanley | 3,005 | $10.0K | 0.00% | −1,070−26.3% | Reduced |
| State Street Corp | 11,424 | $36.0K | 0.00% | +337+3.0% | Added |
| Barclays PLC | 14,553 | $46.0K | 0.00% | +14,553 | New |
| Cambridge Trust Co | 24,609 | $79.0K | 0.00% | 00.0% | Unchanged |
| Federated Hermes, Inc. | 30,636 | $98.0K | 0.00% | +544+1.8% | Added |
| Geode Capital Management, LLC | 41,466 | $132.0K | 0.00% | +1,206+3.0% | Added |
| BlackRock Inc. | 51,334 | $164.0K | 0.00% | −1,035−2.0% | Reduced |
| RBF Capital, LLC | 68,034 | $219.0K | 0.01% | 00.0% | Unchanged |
| Bridgeway Capital Management, LLC | 106,500 | $340.0K | 0.01% | 00.0% | Unchanged |
| Sectoral Asset Management Inc | 541,765 | $1.73M | 0.31% | −10.0% | Reduced |
| Vanguard Group Inc | 556,423 | $1.77M | 0.00% | −23,438−4.0% | Reduced |
| FMR LLC | 966,226 | $3.08M | 0.00% | −1,000−0.1% | Reduced |
| Clough Capital Partners L P | 1,137,764 | $3.63M | 0.28% | −168,862−12.9% | Reduced |
| Decheng Capital Management III (Cayman), LLC | 1,333,254 | $4.25M | 1.30% | +1,333,254 | New |
| Omega Fund Management, LLC | 1,335,050 | $4.26M | 0.87% | 00.0% | Unchanged |
| Medicxi Ventures Management (Jersey) Ltd | 1,501,716 | $4.79M | 1.30% | 00.0% | Unchanged |
| Novo Holdings A/S | 2,161,990 | $6.90M | 0.36% | −8,110−0.4% | Reduced |
| Sofinnova Investments, Inc. | 3,606,707 | $11.5M | 0.97% | 00.0% | Unchanged |
| venBio Partners LLC | 3,673,374 | $11.7M | 2.60% | 00.0% | Unchanged |
| Ensign Peak Advisors, Inc | 0 | $0 | 0.00% | −93,334−100.0% | Sold out |
| Millennium Management LLC | 0 | $0 | 0.00% | −10,633−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −168−100.0% | Sold out |